The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7161-7178

  Cousin, Fabien J ^a,b,h   Jouan Lanhouet, Sandrine ^c,d,i   Théret, Nathalie ^c,d,e   Brenner, Catherine ^f,g   Jouan, Elodie ^c,d   Moigne Muller, Gwénaëlle Le ^c,d   Dimanche Boitrel, Marie Thérése ^c,d   Jan, Gwénaël ^a  

^a UMR1253   (France)

^b Cniel   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e CAMPUS DE BEAULIEU   (France)

^f INSERM   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITÉ DE CAEN   (France)

ⁱ GHENT UNIVERSITY   (Belgium)

Author keywords

Colon cancer; Propionibacterium freudenreichii; RNA microarrays; SCFA; TRAIL

Indexed keywords

ACETIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DRUG METABOLITE; ETOPOSIDE; FLUOROURACIL; OXALIPLATIN; PROBIOTIC AGENT; PROPIONIC ACID; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TNFSF10 PROTEIN, HUMAN; TRANSCRIPTOME;

ADENOCARCINOMA CELL LINE; ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; FLIP GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; ONCOGENE; PROPIONIBACTERIUM FREUDENREICHII; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; XIAP GENE; ANIMAL; BOVINE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; FERMENTED MILK PRODUCT; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CATTLE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CULTURED MILK PRODUCTS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROBIOTICS; PROPIONIBACTERIUM FREUDENREICHII; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84981216578     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6881     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer stastitics. CA.Cancer J.Clin. 2011; 61: 69-90.
2. Cousin FJ, Mater D, Foligné B, Jan G. Dairy propionibacte-ria as human probiotics: A review of recent evidence. Dairy Sci.Technol. 2011; 91: 1-26.
3. Jan G, Belzacq AS, Haouzi D, Rouault A, Métivier D, Kroemer G, Brenner C. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids act-ing on mitochondria. Cell Death Differ. 2002; 9: 179-188.
4. Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propi-onibacteria. Apoptosis. 2007; 12: 573-591.
5. Lan A, Bruneau A, Bensaada M, Philippe C, Bellaud P, Rabot S, Jan G. Increased induction of apoptosis by Propionibacterium freudenreichii TL133 in colonic muco-sal crypts of human microbiota-associated rats treated with 1,2-dimethylhydrazine. Br.J.Nutr. 2008; 100: 1251-1259.
6. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, Corcos L, Jan G. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS.ONE. 2012; 7: e31892.
7. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998; 281: 1305-1308.
8. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J.Clin.Invest. 1999; 104: 155-162.
9. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat.Med. 1999; 5: 157-163.
10. Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem.Biophys.Res. Commun. 1999; 265: 479-483.
11. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based tar-geting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J.Clin.Oncol. 2008; 26: 3621-3630.
12. Sträter J, Walczak H, Pukrop T, Von Müller L, Hasel C, Kornmann M, Mertens T, Möller P. TRAIL and its recep-tors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology. 2002; 122: 659-666.
13. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, de Vries EG, Kleibeuker JH. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin.Cancer Res. 2006; 12: 4350-4356.
14. Naka T Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002; 62: 5800-5806.
15. Stolfi C, Pallone F, Monteleone G. Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int.J.Mol.Sci. 2012; 13: 7886-7901.
16. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis. 2009; 14: 607-623.
17. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999; 59: 6153-6158.
18. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin. Cancer Res. 2001; 7: 350-357.
19. Audy J, Mathieu O, Belvis J, Tompkins TA. Transcriptomic response of immune signalling pathways in intestinal epi-thelial cells exposed to lipopolysaccharides, Gram-negative bacteria or potentially probiotic microbes. Benef. Microbes. 2012; 3: 273-286.
20. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J. BABELOMICS: a suite of web tools for func-tional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 2005; 33: W460-W464.
21. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, Dimanche-Boitrel MT. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene. 2003; 22: 1807-1816.
22. Kiefer J, Beyer-Sehlmeyer G, Pool-Zobel BL. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetyla-tion in human HT29 colon cancer cells. Br.J.Nutr. 2006; 96: 803-810.
23. Cousin FJ, Louesdon S, Maillard MB, Parayre S, Falentin H, Deutsch SM, Boudry G, Jan G. The first dairy product exclusively fermented by Propionibacterium freuden-reichii: a new vector to study probiotic potentialities in vivo. Food Microbiol. 2012; 32: 135-146.
24. Cousin FJ, Foligné B, Deutsch SM, Massart S, Parayre S, Le Loir Y, Boudry G, Jan G. Assessment of the probiotic poten-tial of a dairy product fermented by Propionibacterium freud-enreichii in piglets. J.Agric.Food Chem. 2012; 60: 7917-7927.
25. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'DwyerPJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J.Clin.Oncol. 2010, 28: 2839-2846.
26. Morales JC, Ruiz-Magaña MJ, Carranza D, Ortiz-Ferrón G, Ruiz-Ruiz C. HDAC inhibitors with different gene regula-tion activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apop-tosis. Cancer Lett. 2010, 297: 91-100.
27. van Roosmalen IAM, Quax WJ, Kruyt FAE. Two death-inducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function. Biochem.Pharmacol. 2014; 91: 447-456.
28. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 2004; 23: 6261-6271.
29. Foligné B, Deutsch SM, Breton J, Cousin FJ, Dewulf J, Samson M, Pot B, Jan G. Promising immunomodulatory effects of selected strains of dairy propionibacteria as evi-denced in vitro and in vivo. Appl.Environ.Microbiol. 2010; 76: 8259-8264.
30. Hague A, Elder DJ, Hicks DJ, Paraskeva C. Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int.J.Cancer. 1995; 60: 400-406.
31. Marchetti MC, Migliorati G, Moraca R, Riccardi C, Nicoletti I, Fabiani R, Mastrandrea V, Morozzi G. Possible mechanisms involved in apoptosis of colon tumor cell lines induced by deoxycholic acid, short-chain fatty acids, and their mixtures. Nutr.Cancer. 1997; 28: 74-80.
32. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M. Evaluation of multi-ple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int.J.Cancer. 1999; 84: 545-552.
33. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon can-cer cell phenotype are associated with histone hyperacety-lation. J.Nutr. 2002; 132: 1012-1017.
34. Sealy L, Chalkley R. Modification of histones immediately following synthesis. Arch.Biochem.Biophys. 1979; 197: 78-82.
35. Barnard JA, Warwick G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ. 1993; 4: 495-501.
36. Hodin RA, Meng S, Archer S, Tang R. Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells. Cell Growth Differ. 1996; 7: 647-653.
37. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc.Natl.Acad.Sci.USA. 1998; 95: 6791-6796.
38. Davie JR. Inhibition of histone deacetylase activity by butyrate. J.Nutr. 2003; 133: 2485S-2493S.
39. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carci-noma cells. Apoptosis. 2007; 12: 1465-1478.
40. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery. 2001; 130: 265-272.
41. Fulda S, Debatin KM. HDAC inhibitors: double edge sword for TRAIL cancer therapy? Cancer Biol.Ther. 2005; 4: 1113-1115.
42. Pintzas A, Zhivotovsky B, Workman P, Clarke PA, Linardopoulos S, Martinou JC, Lacal JC, Robine S, Nasioulas G, Andera L. Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. Cancer Biol.Ther. 2012; 13: 458-466.
43. Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br.J.Cancer. 2007; 97: 1028-1034.
44. Liu ZH, Huang MJ, Zhang XW, Wang L, Huang NQ, Peng H, Lan P, Peng JS, Yang Z, Xia Y, Liu WJ, Yang J, Qin HL et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am.J.Clin.Nutr. 2013; 97: 117-126.
45. Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, Poussa T, Mykkänen H, Korpela R. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS on potentially carcinogenic bacterial activity in human colon. Int.J.Food Microbiol. 2008; 128: 406-410.
46. El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, Juvonen RO, Salminen SJ, Poussa T, Mykkänen HM. Probiotic supplementation reduces a bio-marker for increased risk of liver cancer in young men from Southern China. Am.J.Clin.Nutr. 2006; 83: 1199-1203.
47. Puertollano E, Kolida S, Yaqoob P. Biological signifi-cance of short-chain fatty acid metabolism by the intestinal microbiome. Curr.Opin.Clin.Nutr.Metab.Care. 2014; 17: 139-144.
48. Jan G, Leverrier P, Proudy I, Roland N. Survival and ben-eficial effects of propionibacteria in the human gut: in vivo and in vitro investigations. Lait. 2002; 82: 131-144.
49. Hervé C, Fondrevez M, Cheron A, Barloy-Hubler F, Jan G. Transcarboxylase mRNA: a marker which evidences P. freud-enreichii survival and metabolic activity during its transit in the human gut. Int.J.Food Microbiol. 2007; 113: 303-314.
50. Lan A, Bruneau A, Philippe C, Rochet V, Rouault A, Hervé C, Roland N, Rabot S, Jan G. Survival and metabolic activ-ity of selected strains of Propionibacterium freudenreichii in the gastrointestinal tract of human microbiota-associated rats. Br.J.Nutr. 2007; 97: 714-724.
51. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp.Cell Res. 2000; 256: 42-49.
52. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001; 61:1645-1651.
53. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F, Takahashi N, Sergent O, Lagadic-Gossmann D, Vandenabeele P, Samson M, Dimanche-Boitrel MT. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 2012; 19: 2003-2014.